Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A Single Study in Assiut University Hospital (Hemodialysis)

16 de noviembre de 2026 actualizado por: Shimaa Salah Ali

Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A single study in Assiut university hospital

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

End-stage renal failure (ESRF) represents a major global health burden, with hemodialysis being the most common renal replacement therapy. The creation of an arteriovenous fistula (AVF) Is considered the preferred vascular access for long-term hemodialysis due to its superior patency and lower complication rates compared to grafts and catheters (1-2) Despite its advantages, AVF creation may be associated with several complications, including ischemic steal syndrome and ischemic monomelic neuropathy (IMN). Ischemic neuropathy is a rare but potentially disabling complication resulting from acute or chronic ischemia of peripheral nerves following AVF creation. Patients may present with severe pain, sensory disturbances, weakness, and functional impairment of the affected limb (3-5) Early diagnosis remains challenging because symptoms may overlap with uremic neuropathy, diabetic neuropathy, and other peripheral nerve disorders commonly encountered in ESRF patients. Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), provide objective assessment of nerve dysfunction and may facilitate early diagnosis and differentiation from other neuropathic conditions Limited data are available regarding the electrophysiological characteristics of AVF-related ischemic neuropathy, particularly in ESRF populations. Therefore, a comprehensive electrophysiological evaluation may contribute to improved recognition, management, and prevention of long-term disability

Hemodialysis fistula-related ischemic neuropathy is an under-recognized complication in patients with ESRF. Delayed diagnosis may lead to irreversible neurological deficits and impaired quality of life. The electrophysiological features and associated risk factors remain insufficiently characterized in many dialysis populations

This study aims to provide a detailed electrophysiological assessment of ischemic neuropathy associated with AVF creation in ESRF patients. The findings may facilitate early diagnosis, improve clinical outcomes, and contribute to developing screening and management strategies for high-risk patients

Aim of the Work:

To evaluate electrophysiological abnormalities associated with hemodialysis fistula-related ischemic neuropathy in patients with end-stage renal failure

  • Primary Objective To assess peripheral nerve function using nerve conduction studies and electromyography in ESRF patients with AVF-related ischemic neuropathy
  • Secondary Objectives To compare electrophysiological findings between ESRF patients with and without ischemic neuropathy To identify clinical and vascular factors associated with the development of ischemic neuropathy To determine the severity and distribution of nerve involvement To correlate electrophysiological findings with clinical manifestations and duration of AVF use

Patients and methods:

Type of the study: Analytical Cross-Sectional Case-Control Study Study Setting: The study will be conducted at Nephrology and Hemodialysis Unit at Assuit University hospital

Study duration: august 2026 - august 2027 Study populations: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)

  • ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
  • Presence of AVF
  • Clinical manifestations suggestive of ischemic neuropathy after AVF creation
  • Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy Inclusion Criteria Age ≥18 years Diagnosed ESRF on regular hemodialysis Exclusion Criteria Pre-existing hereditary neuropathies Cervical radiculopathy Brachial plexopathy Motor neuron disease. Recent upper limb trauma. Peripheral nerve entrapment syndromes. Severe cognitive impairment. Refusal to participate

Methodology A. Clinical Assessment

All participants will undergo:

Detailed medical history, Dialysis history

AVF characteristics:

Site of fistula Duration since creation Side of fistula Previous vascular interventions

Neurological examination:

Motor assessment Sensory assessment Deep tendon reflexes Muscle strength grading using MRC scale B. Laboratory Investigations Complete blood count (CBC) Serum creatinine Blood urea nitrogen (BUN) Electrolytes HbA1c (for diabetic patients) Serum albumin Calcium and phosphorus levels C. Vascular Assessment Duplex Doppler ultrasonography of AVF Assessment of arterial flow and steal phenomenon D. Electrophysiological Assessment

Nerve Conduction Studies (NCS):

Electromyography (EMG)

Tipo de estudio

De observación

Inscripción (Estimado)

50

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

1 año y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)

  • ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
  • Presence of AVF
  • Clinical manifestations suggestive of ischemic neuropathy after AVF creation
  • Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy

Descripción

Inclusion Criteria:

  • Age ≥18 years
  • Diagnosed ESRF on regular hemodialysis

Exclusion Criteria:

  • Pre-existing hereditary neuropathies
  • Cervical radiculopathy
  • Brachial plexopathy
  • Motor neuron disease.
  • Recent upper limb trauma.
  • Peripheral nerve entrapment syndromes.
  • Severe cognitive impairment.
  • Refusal to participate

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: OTHER
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Motor Nerve Conduction Velocity
Periodo de tiempo: Up to 1 year post-AVF creation

Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second.

Up to 1 year post-AVF creation
Arteriovenous Fistula Blood Flow Volume
Periodo de tiempo: Up to 1 year post-AVF creation

Assessed by Duplex Doppler Ultrasound on the arteriovenous fistula. Measured in milliliters per minute.

Up to 1 year post-AVF creation

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensory Nerve Conduction Velocity
Periodo de tiempo: Up to 1 year post-AVF creation

Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second

Up to 1 year post-AVF creation

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

4 de noviembre de 2026

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de enero de 2028

Fechas de registro del estudio

Enviado por primera vez

4 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir